Developing new drugs to treat aggressive breast cancer
Small Molecule CUL4 Inhibitors as Dual Precision Oncology and Immuno-Oncology Drugs
['FUNDING_OTHER'] · CULNEXIN THERAPEUTICS, INC. · NIH-10673021
This study is looking for new drugs that can specifically target and kill cancer cells in patients with aggressive triple negative breast cancer, while leaving healthy cells unharmed, to improve treatment options for you.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CULNEXIN THERAPEUTICS, INC. (nih funded) |
| Locations | 1 site (PRINCETON JUNCTION, UNITED STATES) |
| Trial ID | NIH-10673021 on ClinicalTrials.gov |
What this research studies
This research focuses on creating small molecule drugs that inhibit the CUL4A protein, which is linked to aggressive forms of triple negative breast cancer (TNBC). The approach involves identifying compounds that can selectively target and kill cancer cells overexpressing CUL4A while sparing healthy tissue. By understanding the role of CUL4A in tumor growth and immune response, the research aims to enhance both targeted and immunotherapy treatments for patients with TNBC. The project includes extensive screening of compounds to find effective inhibitors and evaluating their potential in preclinical models.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with triple negative breast cancer, particularly those with high levels of CUL4A expression.
Not a fit: Patients with other types of breast cancer or those whose tumors do not express high levels of CUL4A may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new targeted treatment option for patients with triple negative breast cancer, potentially improving survival rates and quality of life.
How similar studies have performed: While the specific approach of targeting CUL4A is novel, similar strategies targeting other oncogenic pathways have shown promise in previous cancer research.
Where this research is happening
PRINCETON JUNCTION, UNITED STATES
- CULNEXIN THERAPEUTICS, INC. — PRINCETON JUNCTION, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHOU, PENGBO — CULNEXIN THERAPEUTICS, INC.
- Study coordinator: ZHOU, PENGBO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, Cancer Drug, Neoplastic Disease Chemotherapeutic Agents, anti-cancer drug, anticancer agent